Anna Markel Vaysman

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The oral Factor Xa inhibitor YM-150 is being developed by Astellas Pharma Inc for the prevention of venous thromboembolism (VTE) in patients undergoing surgery and for coronary artery disease. In preclinical thrombosis models, as well as in phase II clinical trials in patients undergoing primary hip replacement surgery, YM-150 was safe and exhibited(More)
OBJECTIVE To determine the overall perception and utilization of the pharmacist managed medication therapy management (MTM) clinic services, by healthcare professionals in a large, urban, university medical care setting. METHODS This was a cross-sectional, anonymous survey sent to 195 healthcare professionals, including physicians, nurses, and pharmacists(More)
  • 1